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Abstract 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic 
has hit the world hard. Millions of people have died due to the infection and several have suffered 
with what are now known as post COVID-19 squeal. Among these squeals one is 
immunosuppression which leaves patients prone to severe opportunistic infection. We here report 
a case of young female who was infected by COVID-19 and later developed cavitary pneumonia 
which upon investigation turned out to be due to mycobacterium tuberculosis.  Through this report 
we aim to highlight the importance of high index of suspicion for infection like Mycobacterium 
tuberculosis after COVID-19 infection which developed in a healthy immunocompetent patient.  
 
Introduction 
Mycobacterium tuberculosis affected 10 million people worldwide in the year 2019, Pakistan is 
among the eight high TB burden countries according to the world health organization (WHO) 
report. Lungs are the most commonly infected organ by mycobacterium tuberculosis. One of the 
most common risk factors of development of the disease is immunosuppression [1]. Ever since 
pandemic of COVID-19 hit the world a lot of opportunistic infection have surfaced most 
commonly reported of which are invasive aspergillosis and pneumocystis infection [2,3]. Although 
Mycobacterium tuberculosis has not been reported extensively as post COVID-19 infection, a 
significant number of reports have predicted rise in the incidence of disease due to current 
pandemic. A few notable studies include Tadolini et al. with a chohort of 49 cases, Nitesh et al. 
with a group of 22 patients and Motta et al. with 69 patients [4-7]. These series describe the 
characteristic of patient with COVI-19 and mycobacterium tuberculosis and their cause of 
mortality. However none of these studies were able to establish a clinical mechanism behind the 
co-infection and establish a temporal relationship between the two. Moreover most of the cases 
described above had either previously been treated for mycobacterium tuberculosis or had already 
been on treatment for it. Hence the aim of our report is to bring to attention the importance of high 
index of suspicion for the disease even in immunocompetent individuals without any risk factors 
for the disease like our patient.  
 
Case Report 
A 26-year-old female presented in pulmonology clinic with fever and hoarseness of voice for 1 
month. The fever was high grade and associated with dry cough. She had a history of mild COVID-
19 pneumonia (Polymerase chain reaction PCR positive) before this illness and was managed at 
home in isolation with antibiotics and oral prednisolone 20 mg twice daily for 14 days.  The patient 
had improved clinically and remain asymptomatic. Before presentation in pulmonology clinic she 
had consulted otolaryngologist who prescribed her azithromycin and voice rest but there was no 
improvement. On examination she was a young female with average height and build with hoarse 
voice. Chest auscultation revealed bronchial breath sound in right mid part of chest. Chest 
radiology was done and showed right mid zone cavitation (Figure 1). Her COVID -19 PCR was 
checked again and came out negative. As she was not producing sputum bronchoscopy was done. 
The bronchoscopy showed mobile inflamed vocal cords, the trachea was coated with white patches 
(Figure 2 a,b) till the right main bronchus, Bronchoalveolar lavage (BAL) was done from right 
upper and middle lobe and were sent for microbiological examination and Xpert MTB/Rif. 
Endobronchial biopsy was taken from the right middle lobe bronchial wall. The BAL Acid Fast 
Bacilli (AFB) smear and Xpert MTB/Rif came out to be positive without rifampicin resistance and 
the biopsy showed caseating granulomas (Figure 3).  BAL Galactomanan came out 0.16, AFB 
culture showed pan sensitive Mycobacterium tuberculosis while bacterial culture was negative. 
The patient was started on anti-tuberculous therapy and was followed up in the clinic. The patient 
was treated for tuberculosis disease with first line anti-tuberculosis drugs including Isoniazid, 
rifampicin, pyrazinamide and ethambutol.  The patient improved clinically became afebrile, 
regained her voice and responded to treatment well Just after 2 weeks of therapy. She is currently 
in intensive phase of therapy. 
 
Discussion 
COVID-19 pandemic has affected people extensively. Not only the virus itself has deleterious 
effects on the lungs but the immunosuppression caused by therapy for virus makes patients 
susceptible to a number of other opportunistic infections [2,3]. Tuberculosis is endemic in our part 
of world but the fact that COVID-19 infection increases its incidence is yet to be established. In 
first case series of a cohort of 49 patient published by Tadolini et al. [4] it was seen that 14 of these 
patients had a diagnosis of TB made after COVID-19 was diagnosed. However, they could not 
conclude whether COVID-19 lead to progression of latent TB to active TB, other explanations 
presented by them were a possible co infection by both organism where COVID-19 was diagnosed 
first due to high index of suspicion or symptoms of COVID-19 brought into clinical evaluation of 
TB in otherwise asymptomatic TB infection. Our patient however had no evidence of symptomatic 
TB before COVID-19 infection, chest x ray had no cavitation and had acute onset of symptoms 
and that were suggestive of COVID infection. Development of active tuberculosis has been well 
reported in patients who have been immunocompromised either by viral infections like HIV or 
have comorbid conditions like diabetes or are on immunosuppressive agents like steroids that 
render their immune system week hence more prone to bacterial infection [8] .More studies that 
can identify a temporal relationship between the two infections are required. The COIVD-19 
pandemic has been projected to bring forward detrimental consequences for TB.  It has been 
estimated that current settings of lock down will limit diagnosis treatment and preventive measure 
of tuberculosis resulting in at least 6.3 million additional cases of tuberculosis between the year 
2020-2025. It is speculated that at least 5 years of progress made towards TB elimination can be 
lost [9-11]. This impact was studied in an observational study done by Giovani et al at 37 TB 
centers located in 16 countries. It was found that during the early period of the pandemic a number 
of aspects of TB management have undergone significant setbacks. Some of the areas highlighted 
included decreased access due to transport interruption, fear of exposure to COVID-19, low 
priority given to TB screening [12]. The above facts are alarming and demand vigilance in our 
diagnosis of tuberculosis in patient who present with symptoms of tuberculosis.  
 
Conclusions 
COVID-19 pandemic may lead to increase in TB cases due to reactivation of latent TB or new 
infection secondary to use of immunosuppressive medication or post viral immune function 
abnormalities. Tuberculosis should be in a differential diagnosis in post COVID-19 cases when 
someone presented with respiratory symptoms and radiological abnormalities. 
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Figure 3. Histopathology of lung showing Granuloma formation with central caseating necrosis 
(arrow) surrounded by epithelioid histiocytes and lymphocytes. (H&E stain, original magnification 
x 100).  
 
